The FDA approved the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults on July 17, removing a major barrier to broader use of the most powerful class of cholesterol-lowering drugs available.
PCSK9 inhibitors were previously available only as injectable medications, a format that many patients declined or discontinued despite its effectiveness. An oral formulation eliminates the need for injections and could dramatically expand the number of Americans who benefit from the drug class.
Heart disease remains the leading cause of death in the United States, killing approximately 700,000 Americans annually. PCSK9 inhibitors can reduce LDL cholesterol by 50% to 60% beyond what statins achieve, making them a critical tool for patients at the highest cardiovascular risk.
An estimated 28 million Americans have high cardiovascular risk and are not adequately controlled on statin therapy alone. Many of these patients are candidates for PCSK9 inhibitors but have not used them due to the inconvenience or discomfort of injections.
The approval is expected to exert competitive pressure on existing injectable PCSK9 products, which include Repatha (evolocumab) and Praluent (alirocumab). Both drugs have seen limited market penetration relative to their clinical potential, partly due to the injection format and partly due to high list prices.
Insurers and pharmacy benefit managers will play a significant role in determining how quickly the oral formulation reaches patients. Coverage decisions, prior authorization requirements and out-of-pocket costs have historically been barriers to PCSK9 inhibitor access.
The FDA’s Center for Drug Evaluation and Research reviewed the oral formulation under standard approval pathways based on clinical trial data demonstrating significant LDL reduction.